AGAMREE (vamorolone)
Duchenne Muscular Dystrophy (DMD)
Key Facts
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals has successfully transitioned from a development-stage entity to a profitable commercial organization focused on rare neuromuscular and neurological diseases. Its strategy centers on acquiring or in-licensing late-stage/commercial assets, maximizing lifecycle value, and maintaining an intense patient-first operational culture. This approach has yielded a marketed portfolio, a growing pipeline, and recognition as a top small-cap company, positioning it for continued growth in specialized therapeutic areas.
View full company profileAbout Catalyst Pharmaceuticals
Catalyst Pharmaceuticals has successfully transitioned from a development-stage entity to a profitable commercial organization focused on rare neuromuscular and neurological diseases. Its strategy centers on acquiring or in-licensing late-stage/commercial assets, maximizing lifecycle value, and maintaining an intense patient-first operational culture. This approach has yielded a marketed portfolio, a growing pipeline, and recognition as a top small-cap company, positioning it for continued growth in specialized therapeutic areas.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy (DMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DT-DEC01 | Dystrogen Therapeutics | Phase 1 |
| Skeletal Muscle Regeneration Program | IPS HEART | Pre-clinical |
| KYMBEE (deflazacort) | Upsher-Smith | Approved |
| ALY688ER | Allysta Pharmaceuticals | Phase 1 |
| AVGN7 + AVGND | AAVogen | Pre-clinical |
| Myomatrix Stabilization Program | Strykagen | Preclinical |
| RIPPLE™ (implied) | SonoThera | Preclinical |
| Vamorolone (AGAMREE) | ReveraGen BioPharma | Approved |
| EDG-5506 | Edgewise Therapeutics | Phase 2 |
| ELEVIDYS (delandistrogene moxeparvovec-rokl) | Sarepta Therapeutics | Marketed / Phase 3 |
| SRP-5051 (vesleteplirsen) | Sarepta Therapeutics | Phase 2 |
| EXONDYS 51 (eteplirsen) | Sarepta Therapeutics | Marketed |